Abstract
Cardiovascular diseases (CVD) are the leading cause of global mortality, but current treatments are only effective in a subset of individuals. To identify new potential treatment targets, we present here the first PWAS for 26 CVDs using plasma proteomics data of the largest cohort to date (53,022 individuals from the UK Biobank Pharma Proteomics Project (UKB-PPP) project).
The GWAS summary data for 26 CVDs spanning 3 categories (16 cardiac diseases, 5 venous diseases, 5 cerebrovascular diseases, up to 1,308,460 individuals). We also conducted replication analyses leveraging two other independent human plasma proteomics datasets, encompassing 7,213 participants from the Atherosclerosis Risk in Communities (ARIC) study and 3,301 individuals from the INTERVAL study.
We identified 94 genes that are consistent with being causal in CVD, acting via their cis-regulated plasma protein abundance. 34 of 45 genes were replicated in at least one of the replication datasets. 41 of the 94 genes are novel genes not implicated in original GWAS. 91.48% (86/94) proteins are category-specific, only two proteins (ABO, PROCR) were associated with diseases in all three CVD categories. Longitudinal analysis revealed that 37 proteins exhibit stable expression in plasma. In addition, PBMC scRNA-seq data analysis showed that 23 of the 94 genes were stably expressed in CD14+ monocytes, implicating their potential utility as biomarkers for CVD disease status. Drug repurposing analyses showed that 39 drugs targeting 23 genes for treating diseases from other systems might be considered in further research.
In conclusion, our findings provide new insights into the pathogenic mechanisms of CVD and offering promising targets for further mechanistic and therapeutic studies.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the National Natural Science Foundation of China (32370653, and 82372458); Innovation Capability Support Program of Shaanxi Province (2022TD-44); Key Research and Development Project of Shaanxi Province (2022GXLH-01-22), and the Fundamental Research Funds for the Central Universities. This study was also supported by the High-Performance Computing Platform and Instrument Analysis Center of Xi an Jiaotong University.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
